Lessons learnt from animal models: Pathophysiology of neuropathic lysosomal storage disorders

Kim M. Hemsley, John J. Hopwood

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Approximately 50 inborn errors of metabolism known as lysosomal storage disorders have been discovered to date, most of which are due to a single mutation in a gene encoding a soluble lysosomal enzyme. Consequently, inadequate enzyme activity results in the accumulation of substrates for that enzyme, invariably accompanied by a wide variety of secondary pathological changes. Many of these conditions remain untreatable, and therefore, research into pathogenic processes and potential treatment strategies is intense. A key tool for researchers in this area is the availability of clinically relevant animal models in which to study disease manifestation and evaluate therapeutic outcomes. Large numbers of both naturally occurring and genetically modified animal models of neurodegenerative lysosomal storage disorders are in existence, with spontaneous models occurring in both large domestic (e.g., cat, dog, sheep) and small (e.g., mouse) animal species. Many have undergone rigorous phenotypic characterization and are now providing us with insights into neurological disease processes. The purpose of this review is to highlight some of the major lessons learnt from these studies.

LanguageEnglish
Pages363-371
Number of pages9
JournalJournal of Inherited Metabolic Disease
Volume33
Issue number4
DOIs
Publication statusPublished - 1 Aug 2010

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

@article{35464de62ebb4515a7cbc6e955802d3a,
title = "Lessons learnt from animal models: Pathophysiology of neuropathic lysosomal storage disorders",
abstract = "Approximately 50 inborn errors of metabolism known as lysosomal storage disorders have been discovered to date, most of which are due to a single mutation in a gene encoding a soluble lysosomal enzyme. Consequently, inadequate enzyme activity results in the accumulation of substrates for that enzyme, invariably accompanied by a wide variety of secondary pathological changes. Many of these conditions remain untreatable, and therefore, research into pathogenic processes and potential treatment strategies is intense. A key tool for researchers in this area is the availability of clinically relevant animal models in which to study disease manifestation and evaluate therapeutic outcomes. Large numbers of both naturally occurring and genetically modified animal models of neurodegenerative lysosomal storage disorders are in existence, with spontaneous models occurring in both large domestic (e.g., cat, dog, sheep) and small (e.g., mouse) animal species. Many have undergone rigorous phenotypic characterization and are now providing us with insights into neurological disease processes. The purpose of this review is to highlight some of the major lessons learnt from these studies.",
author = "Hemsley, {Kim M.} and Hopwood, {John J.}",
year = "2010",
month = "8",
day = "1",
doi = "10.1007/s10545-010-9078-6",
language = "English",
volume = "33",
pages = "363--371",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer Netherlands",
number = "4",

}

Lessons learnt from animal models : Pathophysiology of neuropathic lysosomal storage disorders. / Hemsley, Kim M.; Hopwood, John J.

In: Journal of Inherited Metabolic Disease, Vol. 33, No. 4, 01.08.2010, p. 363-371.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Lessons learnt from animal models

T2 - Journal of Inherited Metabolic Disease

AU - Hemsley, Kim M.

AU - Hopwood, John J.

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Approximately 50 inborn errors of metabolism known as lysosomal storage disorders have been discovered to date, most of which are due to a single mutation in a gene encoding a soluble lysosomal enzyme. Consequently, inadequate enzyme activity results in the accumulation of substrates for that enzyme, invariably accompanied by a wide variety of secondary pathological changes. Many of these conditions remain untreatable, and therefore, research into pathogenic processes and potential treatment strategies is intense. A key tool for researchers in this area is the availability of clinically relevant animal models in which to study disease manifestation and evaluate therapeutic outcomes. Large numbers of both naturally occurring and genetically modified animal models of neurodegenerative lysosomal storage disorders are in existence, with spontaneous models occurring in both large domestic (e.g., cat, dog, sheep) and small (e.g., mouse) animal species. Many have undergone rigorous phenotypic characterization and are now providing us with insights into neurological disease processes. The purpose of this review is to highlight some of the major lessons learnt from these studies.

AB - Approximately 50 inborn errors of metabolism known as lysosomal storage disorders have been discovered to date, most of which are due to a single mutation in a gene encoding a soluble lysosomal enzyme. Consequently, inadequate enzyme activity results in the accumulation of substrates for that enzyme, invariably accompanied by a wide variety of secondary pathological changes. Many of these conditions remain untreatable, and therefore, research into pathogenic processes and potential treatment strategies is intense. A key tool for researchers in this area is the availability of clinically relevant animal models in which to study disease manifestation and evaluate therapeutic outcomes. Large numbers of both naturally occurring and genetically modified animal models of neurodegenerative lysosomal storage disorders are in existence, with spontaneous models occurring in both large domestic (e.g., cat, dog, sheep) and small (e.g., mouse) animal species. Many have undergone rigorous phenotypic characterization and are now providing us with insights into neurological disease processes. The purpose of this review is to highlight some of the major lessons learnt from these studies.

UR - http://www.scopus.com/inward/record.url?scp=77956043666&partnerID=8YFLogxK

U2 - 10.1007/s10545-010-9078-6

DO - 10.1007/s10545-010-9078-6

M3 - Review article

VL - 33

SP - 363

EP - 371

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

IS - 4

ER -